## Is the Physiotherapist of the Future Advanced?

A short Symposium on Advanced Practice Physiotherapy (APP) in Emergency Departments and Orthopedic Clinics





Advanced practice physiotherapy care in emergency departments for patients with musculoskeletal disorders: Preliminary results of a pragmatic randomized controlled trial and cost analysis

François Desmeules, PhD, PT, OPPQ fellow Head of Graduate APP Programs Full Professor, School of Rehabilitation University of Montréal

Researcher, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, Québec, Canada



Université de Montréal et du monde.

## Background

Overcrowding in emergency departments (EDs) worldwide;

· Will worsen with aging populations, physician shortages.

Canada is among the countries with the longest ED waiting times.

Musculoskeletal disorders (MSKD) represent at least 25% of ED visits;

MSKD affect 11 million Canadians per year.

Traditionally, ED physicians are the first-contact practitioners who manage patients with MSKD;

Limited knowledge and confidence in MSKD care.

## Background

New collaborative models of care including physiotherapists in advanced practice roles to help relieve physicians' burden

- Dx and triage
- Ordering medical imaging or prescribing or recommend medications.

Advanced practice physiotherapy (APP) can improve outcomes for patients with MSKD as well as improve resources use in health care systems.

APP models of care are emerging worldwide

- More evidence is needed
- Large high quality, pragmatic RCTs are needed

#### **STUDY PROTOCOL**

**Open Access** 

Advanced practice physiotherapy care in emergency departments for patients with musculoskeletal disorders: a pragmatic cluster randomized controlled trial and cost analysis

E. Matifat<sup>1</sup>, E. Berger Pelletier<sup>2</sup>, R. Brison<sup>3</sup>, L. J. Hébert<sup>4,5</sup>, J.-S. Roy<sup>4,5</sup>, L. Woodhouse<sup>6</sup>, S. Berthelot<sup>7</sup>, R. Daoust<sup>7</sup>, M.-J. Sirois<sup>5</sup>, R. Booth<sup>8</sup>, R. Gagnon<sup>4,5</sup>, J. Miller<sup>8</sup>, Y. Tousignant-Laflamme<sup>9</sup>, M. Emond<sup>7</sup>, K. Perreault<sup>4,5</sup> and F. Desmeules<sup>1,10\*</sup>

Full article in preparation to be submitted

## Objectives

To evaluate the impact of an APP-led model of care compared to usual physician ED care for patients with a minor MSKD.


#### Specific objectives:

- 1. Compare effectiveness of care in terms of patients-related outcomes;
- 2. Compare healthcare resource utilization;
- 3. Compare wait times and ED lenght of stay.
- 4. Compares direct costs and perform a cost-utility analysis



#### Methods

- Stepped wedge pragmatic multicenter trial
- 6 Canadian EDs
- 12 APP trained physiotherapists
- Participants were not blinded



- EQ-5D-5L
- Relevant Disability Questionnaires (DASH, NDI, Oswestry or LEFS)

During follow-up participants will complete a treatment diary:

Any co-interventions (including treatments, medical interventions, use of medication)

Allocation

## Methods

#### Inclusion criteria:

- ✓ Adults with MSKD
- ✓ Level 3, 4 or 5 on the Canadian Triage and Acuity Scale Exclusion criteria:
  - χ Significant trauma or major MSKD or injury,
  - χ Red flags,
  - χ Patients with diagnosed inflammatory arthritis,
  - χ Active/unstable non-MSKD conditions,
  - χ Work-related MSKD eligible for workers' compensation benefits.

STUDY PROTOCOL Open Access




Advanced practice physiotherapy care in emergency departments for patients with musculoskeletal disorders: a pragmatic cluster randomized controlled trial and cost analysis


E. Matifat<sup>1</sup>, E. Berger Pelletier<sup>2</sup>, R. Brison<sup>3</sup>, L. J. Hébert<sup>4,5</sup>, J.-S. Roy<sup>4,5</sup>, L. Woodhouse<sup>6</sup>, S. Berthelot<sup>7</sup>, R. Daoust<sup>7</sup>, M.-J. Sirois<sup>5</sup>, R. Booth<sup>8</sup>, R. Gagnon<sup>4,5</sup>, J. Miller<sup>8</sup>, Y. Tousignant-Laflamme<sup>9</sup>, M. Emond<sup>7</sup>, K. Perreault<sup>4,5</sup> and F. Desmeules<sup>1,10\*</sup>



## APP model of care



#### Results



#### Results



**APP: 49.8% female** 

Usual: 55.3% female



**APP:** 44.7 years ± 17.9

**Usual: 46.5 years ± 19.4** 



**College or University** 

**Usual: 62.8%** 

**APP: 57.1%** 




**CTAS** 

Usual: P3: 23.4%, P4: 47.9%, P5: 29.0%

APP: P3: 36.9%, P4: 36.2%, P5: 26.8%

Results

Ankle & Foot Knee Low Back Shoulder



## Results – ED Care provided

	Usual care group	APP care group	Chi-square	P value	
	n=376	n=287			
Medical imaging prescribed					
X-Ray	243 (64.6)	186 (64.8)	0.002	0.962	
CT-scan	20 (5.3)	10 (3.5)	1.268	0.260	
MRI	6 (1.6)	7 (2.4)	0.602	0.438	
Ultrasound	11 (2.9)	10 (3.5)	0.166	0.684	
Medication prescribed					
Analgesics	122 (32.4)	92 (32.1)	0.011	0.915	
NSAIDs	126 (33.5)	88 (30.7)	0.604	0.437	
Opioids	52 (13.8)	39 (13.6)	0.008	0.929	
Muscle relaxants	21 (5.6)	11 (3.8)	1.088	0.297	
Referral to other medical or health	14 (3.7)	15 (5.2)	0.879	0.348	
professionals within ED					
Discharge plan					
Discharge home	371 (98.7)	279 (97.2)	1.799	0.180	
Hospitalization	5 (1.3)	8 (2.8)	1.799	0.100	

## Results – Care provided in the ED

	Usual care group <sup>a</sup>	APP care group	Chi square	P value
	n=376	n=287		
Advice and education	256 (68.27)	269 (93.73)	64.22	<0.001
Walking aids and orthosis	95 (25.33)	90 (31.36)	2.93	0.087
Supervised outpatient physiotherapy	92 (24.53)	158 (55.05)	64.43	<0.001
Home exercises	27 (7.20)	125 (43.55)	121.47	<0.001

<sup>&</sup>lt;sup>a</sup>Missing data: 1

#### Results – Initial ED visit



	Mean	Median (Quartiles)	P-value
Wait times (minutes)			
Usual care group <sup>a</sup>	188.97	133 (80-249)	<0.01
APP care group	116.52	96 (65-148)	
Length of stay in the ED (minutes)			
Usual care group <sup>b</sup>	295.26	241.5 (157-375.75)	0.20
APP care group	277.99	217 (163-310.5)	
<sup>a</sup> Missing data: 1		·	

<sup>b</sup>Missing data:2



	Group	Mean (±SD)	Median (Quartiles)	p value
Modified VSQ-9	Usual care <sup>a</sup>	71.9 (23.98)	75 (54.2 – 92.9)	
(0-100)				<0.001
				-
	APP care <sup>b</sup>	90.5 (14.56)	100 (85.7-100)	

<sup>a</sup>Missing data: 27 <sup>b</sup>Missing data: 13

#### Results – Primary Outcome BPI-I and BPI-S

			Usual	care	group		APP	care gi	roup	Between-group difference		
		n	Mean	SD	95%CI	n	Mean	SD	95%CI	Mean (95%CI)	р	
											value	
BPI-I	Baseline	376	5.47	2.36	5.23 - 5.71	287	5.82	2.35	5.55 - 6.10			
(0-10)	4 weeks	257	2.67	2.62	2.35 - 2.99	185	2.64	2.44	2.29 – 2.99	-0.44 (-0.93 to 0.05)	0.029	
	12 weeks	231	2.02	2.52	1.69 – 2.34	171	1.79	2.32	1.44 – 2.14	-0.66 (-1.16 to -0.15)		
	26 weeks	232	1.56	2.50	1.23 – 1.88	172	1.30	2.15	0.98 – 1.62	-0.62 (-1.12 to -0.11)		
BPI-S	Baseline	376	5.34	2.12	5.12 – 5.55	286	5.41	2.16	5.16 – 5.66			
(0-10)	4 weeks	256	2.31	2.20	2.04 – 2.58	182	2.31	2.18	1.99 – 2.63	-0.10 (-0.52 to 0.32)		
	12 weeks	229	1.97	2.37	1.66 – 2.28	171	1.70	2.03	1.39 – 2.00	-0.48 (-0.91 to -0.05)	0.149	
	26 weeks	232	1.61	2.30	1.31 – 1.90	172	1.43	1.98	1.14 – 1.73	-0.28 (-0.71 to 0.15)		

## Results - Secondary Disability Outcomes

			Usı	ıal care ç	group		AP	P care g	roup	Between-group differ	ence
		n	Mean	SD	95%CI	n	Mean	SD	95%CI	Mean (95%CI)	p value
ODI	<b>Baseline</b>	88	47.72	19.16	43.72 – 51.73	52	46.81	20.18	41.32 - 52.29		
(0-100)	4 weeks	48	27.19	22.06	20.95 - 33.43	34	24.59	10.18	17.81 – 31.38	0.31 (-8.08 to 8.71)	
	12 weeks	41	20.91	19.10	15.06 – 26.76	37	18.71	19.84	12.32 – 25.10	-0.63 (-9.24 to 7.98)	0.981
	26 weeks	48	19.83	21.13	13.85 - 25.81	32	14.19	17.26	8.21 - 20.17	-1.51 (-10.06 to 7.04)	
NDI	Baseline	20	40.36	19.88	31.64 – 49.07	15	41.87	17.21	33.16 – 50.58		
(0-100)	4 weeks	13	16.82	15.96	8.14 – 25.50	6	48.67	22.76	30.46 - 66.88	28.21 (8.47 to 47.94)	
	12 weeks	13	22.92	19.50	12.32 – 33.53	8	29.75	25.80	11.87 – 47.63	9.52 (-8.68 to 27.72)	0.051
	26 weeks	11	29.45	26.46	13.82 – 45.09	7	22.00	22.66	5.22 – 38.78	2.30 (-18.15 to 22.75)	
LEFS	Baseline	218	30.54	20.66	27.80 - 33.29	165	29.15	19.83	26.13 – 32.18		
(100-0)	4 weeks	155	59.18	27.38	54.87 - 63.49	100	60.06	27.91	54.59 - 65.53	2.39 (-4.41 to 9.19)	
	12 weeks	136	73.42	27.89	68.73 – 78.11	93	74.17	23.25	69.44 – 78.89	2.62 (-4.41 to 9.65)	0.694
	26 weeks	133	78.31	27.83	73.58 - 83.04	98	76.06	28.78	70.36 - 81.76	-1.27 (-8.25 to 5.72)	
Quick-DASH	Baseline	109	55.96	23.86	51.48 - 60.44	91	58.09	21.60	53.66 - 62.53		
(0-100)	4 weeks	69	30.70	24.15	25.00 - 36.40	59	32.63	22.09	26.99 -38.26	-0.66 (-8.01 to 6.69)	
	12 weeks	61	22.54	23.29	16.70 – 28.38	50	18.05	18.25	12.99 – 23.10	-7.34 (-15.17 to 0.48)	0.228
	26 weeks	63	13.85	19.66	9.00 – 18.71	49	10.85	14.26	6.86 – 14.85	-4.96 (-12.76 to 2.85)	

Negative values for the ODI, NDI and Quick-DASH are in favor of the APP group. Positive values for the LEFS are in favor of the APP group.

Université **m**de Montréal et du monde.

#### Results – Outcomes

			Usı	ıal care (	group		AP	P care g	roup	Between-group difference	
		n	Mean	SD	95%CI	n	Mean	SD	95%CI	Mean (95%CI)	p value
EQ-5D-5L	Baseline	375	0.47	0.25	0.44 - 0.49	286	0.48	0.24	0.45 - 0.50		
(1-0)	4 weeks	250	0.76	0.20	0.73 - 0.78	181	0.76	0.18	0.74 - 0.79	-0.01 (-0.05 to 0.03)	
	12 weeks	225	0.82	0.17	0.80 - 0.84	168	0.83	0.15	0.81 - 0.85	0 (-0.04 to 0.05)	0.953
	26 weeks	226	0.83	0.18	0.81 - 0.86	171	0.85	0.15	0.83 - 0.87	0 (-0.04 to 0.05)	
EQ-VAS	Baseline	369	61.69	23.19	59.33 – 64.06	274	59.90	23.49	57.12 – 62.68		
(100-0)	4 weeks	245	70.44	21.64	67.73 – 73.15	168	72.33	18.76	69.49 – 75.16	3.35 (-0.99 to 7.69)	
	12 weeks	223	76.77	20.72	74.05 – 79.49	155	76.15	18.81	73.19 – 79.11	1.63 (-2.85 to 6.12)	0.400
	26 weeks	221	80.38	18.83	77.90 -82.87	163	78.49	19.70	75.47 – 81.52	-0.19 (-4.63 to 4.25)	
NPS	Before	349	52.38	25.19	49.74 – 55.03	280	56.49	23.37	53.75 – 59.23	4.11 (0.26 to 7.95)	0.036
(0-100)	discharge										

Positive values for the EQ-5D-5L and EQ-VAS are in favor of the APP group.



## Results – Adverse events (6 cases)

- Imaging: 2 cases where physicians wanted imaging
  - No missed Fx
- Medication: APPT recommended NSAIDs, but not advised due to hypertension.
- Discharge: APPT recommended discharge, but patient was seen by orthopaedics and then discharged.
- Discharge: APPT recommended discharge, but patient was admitted to internal medicine.
- Discharge: skin abrasions that needed cleaning before de Montréal et du monde de Montréal et du monde de Montréal et du monde

Patients had a <u>positive</u> care experience and are highly <u>satisfied</u> with the care received

"The physiotherapist was really good, she really <u>listened</u> to my problem."

"I believe it's one of the times I don't have anything to say about my visit to the emergency room." Patients perceived PPAs as competent first-contact healthcare providers in the emergency department.

"They give great advices, perhaps even better ones than a physician who sees a bit of everything."

"Even if it's responsabilities that physiotherapist didn't have before, [...] they can manage all that. [...] A great progress for Quebec."

Received: 14 June 2024 | Revised: 18 June 2024 | Accepted: 20 June 20

RESEARCH ARTICLE

WILEY

Patients presenting with musculoskeletal disorders in the emergency department: A qualitative study of their experiences when cared by advanced practice physiotherapists in the province of Québec

Juliette Blondin<sup>1,2</sup> ○ | François Desmeules<sup>1,2</sup> ○ | Eveline Matifat<sup>1,2</sup> | Amélie Kechichian<sup>1,3</sup>

Patients are <u>in favor</u> of the implementation of this new model of care and find it beneficial.

"(...) it can somehow reduce physician's workload and maybe reduce waiting times in the emergency room."

"(...) medication, I'd prefer to have it prescribed by a physician, or [...] that the physiotherapist suggestion be validated by a pyshician."



## The APP model in the ED demonstrates benefits

#### Discussion

- Clinical outcomes
  - No differences at 4 weeks
  - Small potentially clinical important differences at 3 and 6 months
- Higher patient satisfaction
- Reduced wait times
- Resource utilization comparable at the initial visit
  - Systematic medical directives sometimes applied for both arms



#### Discussion

Protocol deviation

ED Physicians modified APP care plan
related to personal preferences (60% of cases imaging was added or medication modified)

Follow-up lower than expected (68% at 6 months)
Trial took place during the COVID crisis

Full resource usage and cost-analysis underway

- TDABC direct cost evaluation
- Cost-utility comparison (QALY with EQ5D)



#### **Trial registration**

ClinicalTrials.govNCT05545917. Registered on September 19, 2022.

#### **Funding**

This research is funded by the Canadian Institutes of Health Research (CIHR) (202010PJT-451693-CIB-CFCC-130299).









# Merci! Tak!

